Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Turkova

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
The Lancet. Child & Adolescent Health|March 20, 2025
Simplifying medicine dosing for children by harmonising weight bands across therapeutic areasHylke Waalewijn, Mounier Almett, Roeland E Wasmann, et al.
Child Neuropsychology : a Journal on Normal and Abnormal Development in Childhood and Adolescence|June 23, 2025
Brain MRI and neurocognitive characteristics of children and adolescents living with HIVManuela Martín-Bejarano García, Charlotte Jackson, Liubov Okhonskaia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 22, 2021
Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and FormulationsChishala Chabala, Anna Turkova, Anneke C Hesseling, et al.
JHEP Reports : Innovation in Hepatology|October 12, 2023
Reply to: "Does currently recommended maternal antiviral prophylaxis against mother-to-child transmission of hepatitis B virus require enhancement?"Philippa C Matthews, Ponsiano Ocama, Su Wang, et al.
JHEP Reports : Innovation in Hepatology|August 9, 2023
Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virusPhilippa C Matthews, Ponsiano Ocama, Su Wang, et al.
The Lancet. HIV|August 9, 2020
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trialPauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, et al.
The Lancet. HIV|February 21, 2022
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trialHylke Waalewijn, Man K Chan, Pauline D J Bollen, et al.
Clinical Pharmacokinetics|August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and AdolescentsHardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
BMC Medical Research Methodology|February 21, 2022
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trialRebecca M Turner, Anna Turkova, Cecilia L Moore, et al.
The Lancet. HIV|February 20, 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialEllen White, Cissy Kityo, Moira J Spyer, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
The Lancet. Child & Adolescent Health|March 20, 2025
Simplifying medicine dosing for children by harmonising weight bands across therapeutic areasHylke Waalewijn, Mounier Almett, Roeland E Wasmann, et al.
Child Neuropsychology : a Journal on Normal and Abnormal Development in Childhood and Adolescence|June 23, 2025
Brain MRI and neurocognitive characteristics of children and adolescents living with HIVManuela Martín-Bejarano García, Charlotte Jackson, Liubov Okhonskaia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 22, 2021
Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and FormulationsChishala Chabala, Anna Turkova, Anneke C Hesseling, et al.
JHEP Reports : Innovation in Hepatology|October 12, 2023
Reply to: "Does currently recommended maternal antiviral prophylaxis against mother-to-child transmission of hepatitis B virus require enhancement?"Philippa C Matthews, Ponsiano Ocama, Su Wang, et al.
JHEP Reports : Innovation in Hepatology|August 9, 2023
Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virusPhilippa C Matthews, Ponsiano Ocama, Su Wang, et al.
The Lancet. HIV|August 9, 2020
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trialPauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, et al.
The Lancet. HIV|February 21, 2022
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trialHylke Waalewijn, Man K Chan, Pauline D J Bollen, et al.
Clinical Pharmacokinetics|August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and AdolescentsHardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
BMC Medical Research Methodology|February 21, 2022
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trialRebecca M Turner, Anna Turkova, Cecilia L Moore, et al.
The Lancet. HIV|February 20, 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialEllen White, Cissy Kityo, Moira J Spyer, et al.
Pageof 9